Guido Baietto

Dr. Guido Baietto

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FBFrancesco Bertuccio
Francesco Bertuccio
SMSimone Montini
Simone Montini
MFMaria Antonietta Fusco
Maria Antonietta Fusco
AGAntonella Di Gennaro
Antonella Di Gennaro
GSGaetano Sciandrone
Gaetano Sciandrone
Giulia Maria StellaGiulia Maria Stella
Giulia Maria Stella
Background: Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6–18 months. Objectives: The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy. Methods: This review examines advancements in understanding PM’s genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets. Results: We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.

10 November 2026 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
GBGuido Baietto
Guido Baietto
PRPau Mateo Ramos
Pau Mateo Ramos
AFArianna Farronato
Arianna Farronato
ABAlessandro Berni
Alessandro Berni
ANAnna Chiara Nanto
Anna Chiara Nanto
GMGiulio Melloni
Giulio Melloni

24 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
GFGabriele Ferrari
Gabriele Ferrari
Giulia Maria StellaGiulia Maria Stella
Giulia Maria Stella
GGGiulia Galli
Giulia Galli
SBSabrina Borgetto
Sabrina Borgetto
ILIrene Lanzetta
Irene Lanzetta
FAFrancesco Agustoni
Francesco Agustoni
Background: Malignant mesothelioma is a rare and aggressive tumor, primarily affecting the pleural lining of the lungs. Our study aims to assess the survival benefit of chemotherapy rechallenge, in patients with no further chemotherapy options, compared to best supportive care, and to identify predictive factors for response to this strategy.Materials and Methods: We retrospectively analyzed data from 163 patients affected by MPM since November 2018. Of these, 41 patients, with advanced stage of disease and previously treated, were evaluated for chemotherapy rechallenge with platinum-pemetrexed regimen or were candidate only to palliative and supportive care. These two populations were compared in terms of overall survival outcomes.Results: When comparing median survival times, a significant difference was observed between the two study groups, with patients treated with platinum-pemetrexed rechallenge reaching approximately 20 months of median survival, while those receiving palliative care only 3 months. Survival percentages at different time intervals show that five months after the decision to undergo rechallenge or begin palliative care, the survival rate for the latter group was 27.27%, which is significantly lower than the 81.57% survival rate in the rechallenge one. Cox regression analysis confirmed rechallenge as a significant predictor of improved survival (HR 0.12, p < 0.001). Conclusion: Our findings suggest a potential survival benefit associated with the use of platinum-pemetrexed rechallenge in selected patients with advanced-stage, pretreated MPM. Further studies with larger cohorts are needed to validate these results.